KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Short-Term Debt issuances (2016 - 2025)

Pfizer (PFE) has disclosed Short-Term Debt issuances for 17 consecutive years, with -$796.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-Term Debt issuances changed N/A to -$796.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$796.0 million, a 69.27% increase, with the full-year FY2025 number at -$796.0 million, up 69.27% from a year prior.
  • Short-Term Debt issuances was -$796.0 million for Q4 2025 at Pfizer, up from -$1.5 billion in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $4.2 billion in Q3 2022 to a low of -$2.0 billion in Q1 2024.
  • A 5-year average of $315.9 million and a median of -$11.0 million in 2021 define the central range for Short-Term Debt issuances.
  • Biggest YoY gain for Short-Term Debt issuances was 31166.67% in 2024; the steepest drop was 18636.36% in 2024.
  • Pfizer's Short-Term Debt issuances stood at $265.0 million in 2021, then soared by 228.3% to $870.0 million in 2022, then soared by 275.52% to $3.3 billion in 2023, then plummeted by 145.58% to -$1.5 billion in 2024, then skyrocketed by 46.54% to -$796.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Short-Term Debt issuances are -$796.0 million (Q4 2025), -$1.5 billion (Q3 2024), and $938.0 million (Q2 2024).